Q1: 2026-05-05 Earnings Summary

EPS of -$0.90 beats by $0.18

|

Revenue of

$141.00K

(95.83% Y/Y)

beats by $113.25K

Viridian Therapeutics, Inc. ( VRDN ) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease May 5, 2026 8:00 AM EDT

Company Participants

Greg Rossino

Stephen Mahoney - CEO, President & Director

Radhika Tripuraneni - Chief Medical Officer

Anthony Casciano - Chief Commercial Officer

Shan Wu - Chief Business Officer

Conference Call Participants

Faisal Khurshid - Jefferies LLC, Research Division

Nathanael Charoensook - Leerink Partners LLC, Research Division

Laura Chico - Wedbush Securities Inc., Research Division

Rami Katkhuda - LifeSci Capital, LLC, Research Division

Michael Yee - UBS Investment Bank, Research Division

Joseph Thome - TD Cowen, Research Division

Anish Nikhanj - Truist Securities, Inc., Research Division

Douglas Tsao - H.C.…